Systemic Mastocytosis Clinical Trial
Official title:
Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations
The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Imatinib Mesylate therapy in patients with systemic mastocytosis lacking KIT mutations.
In vitro studies have proven that imatinib inhibits wild type Kit (wtKit) and suppresses
proliferation of the HMC-1V560G cell line, while it is ineffective on inhibiting the growth
of HMC-1V560G, D816V cells. Apart from wtKit, Kit molecules carrying mutations in the
extracellular, transmembrane and juxtamembrane domains, such as V560G, F522C and K509I,
remain sensitive to imatinib. In contrast, several experiments have provided compelling
evidence regarding the resistance against the growth-inhibitory effects of imatinib on cells
carrying the D816V KIT mutation. As a consequence, sensitive and specific methods should be
used in order to avoid "false" KIT mutation-negative cases and, for that purpose, mainly in
cases with low bone marrow mast cell numbers, mutational studies should be performed using
highly purified bone marrow mast cells by means of Facs sorting systems better than whole
bone marrow, unsorted mononuclear cell fraction or mononuclear cell fraction pre-enriched
using magnetic beads conjugated with anti-CD25 monoclonal antibody. In the present study
mutational studies were performed in all cases in purified bone marrow mast cells (purity >
97%) using a FACSaria system (Becton-Dickinson Biosciences) as previously described.
Patients without B or C findings according to the World Health Organization, and without
features of biological progression of the disease receive oral Imatinib Mesylate 300 mg
daily for up to 12 months or until clinical progression/unacceptable toxicity. Patients with
B or C findings or biological progression initially receive oral Imatinib Mesylate 300 mg
daily for two weeks; then, dose is increased up to 400 mg/day except in patients who develop
hematological or any other dose-limiting toxicity.
Biological progression is defined as the presence of at least one of the following features:
i) increased serum tryptase levels > 200 ng/mL, ii) diffuse bone sclerosis, iii) patchy
sclerosis with osteolysis and increased risk of bone fracture or significant bone pain, and,
iv) organomegalies or lymph node enlargement due to mastocytosis.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01807598 -
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
|
Phase 2 | |
Completed |
NCT00171912 -
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
|
Phase 2 | |
Completed |
NCT02441166 -
Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
|
N/A | |
Withdrawn |
NCT03739606 -
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
|
Phase 2 | |
Not yet recruiting |
NCT00979160 -
Evaluation of Response of Dasatinib to Treat Mastocytosis
|
Phase 2 | |
Active, not recruiting |
NCT04681105 -
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT01602939 -
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
|
Phase 2/Phase 3 | |
Completed |
NCT03401060 -
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
|
Phase 3 | |
Terminated |
NCT02415608 -
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
|
Phase 2 | |
Completed |
NCT02478957 -
Treatment of Indolent Systemic Mastocytosis With PA101
|
Phase 2 | |
Terminated |
NCT00918931 -
Obatoclax for Systemic Mastocytosis
|
Phase 2 | |
Completed |
NCT00493129 -
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
|
Phase 2 | |
Terminated |
NCT03214666 -
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01334996 -
Use of Tamoxifen in Systemic Mastocytosis
|
||
Completed |
NCT00449748 -
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
|
Phase 2 | |
Completed |
NCT00109707 -
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
|
Phase 1/Phase 2 |